Clinical Trial Update: Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating azacitidine and entinostat in recurrent advanced non-small cell lung cancer completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Entinostat (entinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-05-09